The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients

Summary

This is a single-arm, open-label, multicenter study designed to evaluate the efficacy, safety, tolerability as well as pharmacodynamics of tafamidis meglumine in ATTR-PN participants in China. Approximately 10-15 participants are planned to be enrolled. All enrolled participants will receive oral tafamidis meglumine 20 mg soft capsules once daily for 72 weeks (18 months).

Timeline

Start

2021-04-28

Primary completion

2023-02-12

Completion

2023-02-12

Drugs

Indications